MYLAN-NABUMETONE TABLET

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

NABUMETONE

Dostupno od:

MYLAN PHARMACEUTICALS ULC

ATC koda:

M01AX01

INN (International ime):

NABUMETONE

Doziranje:

500MG

Farmaceutski oblik:

TABLET

Sastav:

NABUMETONE 500MG

Administracija rute:

ORAL

Jedinice u paketu:

100

Tip recepta:

Prescription

Područje terapije:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Proizvod sažetak:

Active ingredient group (AIG) number: 0122821001; AHFS:

Status autorizacije:

CANCELLED POST MARKET

Datum autorizacije:

2017-01-09

Svojstava lijeka

_ _
_Product Monograph –Mylan_
-
_Nabumetone _
_Page 1 _
PRODUCT MONOGRAPH
PR
MYLAN-NABUMETONE
(NABUMETONE TABLETS, BP)
500 MG
NONSTEROIDAL ANTI-INFLAMMATORY AGENT
Mylan Pharmaceuticals ULC
Date of Revision: May 3, 2011
85 Advance Road
Etobicoke, ON
Canada
Control No.: 145416
_ _
_Product Monograph –Mylan_
-
_Nabumetone _
_Page 2_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND
PRECAUTIONS.................................................................................
4
ADVERSE
REACTIONS...................................................................................................
9
DRUG INTERACTIONS
.................................................................................................
13
DOSAGE AND
ADMINISTRATION.............................................................................
14
OVERDOSAGE
...............................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 14
STORAGE AND
STABILITY.........................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 17
PART II: SCIENTIFIC INFORMATION
...............................................................................
18
PHARMACEUTICAL
INFORMATION.........................................................................
18
CLINICAL
TRIALS.........................................................................................................
19
DETAILED
PHARMACOLOGY...........................